# China NMPA Inspection - Jiujiang Jaguar Pharmaceutical & Medical Device Co., Ltd. - August 13, 2020

Source: https://www.globalkeysolutions.net/records/china_inspection/jiujiang-jaguar-pharmaceutical-medical-device-co-ltd/aa0e6f31-8746-44c8-b5a1-9acfd1cefd15/
Source feed: China

> China NMPA unannounced inspection for Jiujiang Jaguar Pharmaceutical & Medical Device Co., Ltd. published August 13, 2020. The Jiangxi Provincial Drug Administration conducted unannounced inspections of 12 cosmetics manufacturers during June and July 2020. These inspection

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement from the Jiangxi Provincial Drug Administration Regarding the Supervision and Inspection of Cosmetic Manufacturers
- Company Name: Jiujiang Jaguar Pharmaceutical & Medical Device Co., Ltd.
- Publication Date: 2020-08-13
- Product Type: cosmetics
- Summary: The Jiangxi Provincial Drug Administration conducted unannounced inspections of 12 cosmetics manufacturers during June and July 2020. These inspections aimed to ensure enterprises fully comply with their primary responsibility for quality and safety, operating within the regulatory framework overseen by the National Medical Products Administration (NMPA). Across the board, companies such as Jiujiang Jaguar Pharmaceutical & Medical Equipment Co., Ltd., Jiangxi Qicao Pharmaceutical Co., Ltd., and Jiangxi Ideal Industry Co., Ltd. were cited for multiple serious and minor defects.

Additional significant issues included non-standardized or incomplete filing materials for domestically produced non-special-use cosmetics (Jiangxi Jinggang Yaofang Biotechnology Co., Ltd.), labeling issues for registered products (Jiangxi Luyuantang Pharmaceutical Co., Ltd.), and missing relevant materials (Ganzhou Aolier Cosmetics Co., Ltd.). Ganzhou Aolier also had a workshop's cosmetic production suspended due to its use for COVID-19 prevention materials. Jiangxi Jinsikang Pharmaceutical Co., Ltd. received the most severe findings, with seven serious and twelve general deficiencies, resulting in a mandatory production suspension until full rectification and bureau confirmation.

All inspected companies were required to rectify the identified defects and submit a report on their rectification status to the Jiangxi Provincial Drug Administration within 30 days. For companies with suspended production, resumption is contingent upon completing rectification and receiving explicit confirmation from the bureau.

Company: https://www.globalkeysolutions.net/companies/jiujiang-jaguar-pharmaceutical-medical-device-co-ltd/e3c2eb70-100e-4d5f-a2f9-18101204350d/